MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- SUN PHARMA - STERLING BIOTECH
SUN PHARMA vs STERLING BIOTECH - Comparison Results
SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
STERLING BIOTECH
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
Current Valuations
| SUN PHARMA | STERLING BIOTECH | SUN PHARMA/ STERLING BIOTECH |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 28.0 | -0.4 | - | View Chart |
| P/BV | x | 2.9 | 0.0 | 20,669.7% | View Chart |
| Dividend Yield | % | 0.4 | 0.0 | - |
Financials
 SUN PHARMA  STERLING BIOTECH |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-18 |
STERLING BIOTECH Dec-13 |
SUN PHARMA/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 701 | 11 | 6,671.4% | |
| Low | Rs | 433 | 3 | 12,741.2% | |
| Sales per share (Unadj.) | Rs | 110.4 | 26.8 | 411.9% | |
| Earnings per share (Unadj.) | Rs | 11.0 | -15.0 | -73.4% | |
| Cash flow per share (Unadj.) | Rs | 17.2 | -5.5 | -315.4% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 158.8 | 54.9 | 289.4% | |
| Shares outstanding (eoy) | m | 2,399.26 | 267.87 | 895.7% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 5.1 | 0.3 | 1,980.3% | |
| Avg P/E ratio | x | 51.6 | -0.5 | -11,112.7% | |
| P/CF ratio (eoy) | x | 32.9 | -1.3 | -2,586.1% | |
| Price / Book Value ratio | x | 3.6 | 0.1 | 2,818.8% | |
| Dividend payout | % | 18.2 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,360,021 | 1,862 | 73,052.7% | |
| No. of employees | `000 | 17.8 | 1.4 | 1,313.8% | |
| Total wages/salary | Rs m | 53,671 | 547 | 9,815.4% | |
| Avg. sales/employee | Rs Th | 14,890.9 | 5,303.3 | 280.8% | |
| Avg. wages/employee | Rs Th | 3,017.1 | 403.8 | 747.1% | |
| Avg. net profit/employee | Rs Th | 1,480.6 | -2,959.0 | -50.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 264,895 | 7,181 | 3,689.0% | |
| Other income | Rs m | 8,388 | 43 | 19,689.2% | |
| Total revenues | Rs m | 273,282 | 7,223 | 3,783.3% | |
| Gross profit | Rs m | 56,081 | 947 | 5,922.6% | |
| Depreciation | Rs m | 14,998 | 2,543 | 589.7% | |
| Interest | Rs m | 5,176 | 4,377 | 118.2% | |
| Profit before tax | Rs m | 44,295 | -5,931 | -746.9% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -9,505 | 0 | - | |
| Tax | Rs m | 8,452 | -1,924 | -439.2% | |
| Profit after tax | Rs m | 26,338 | -4,007 | -657.4% | |
| Gross profit margin | % | 21.2 | 13.2 | 160.5% | |
| Effective tax rate | % | 19.1 | 32.4 | 58.8% | |
| Net profit margin | % | 9.9 | -55.8 | -17.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 316,359 | 14,335 | 2,206.9% | |
| Current liabilities | Rs m | 198,643 | 49,809 | 398.8% | |
| Net working cap to sales | % | 44.4 | -494.0 | -9.0% | |
| Current ratio | x | 1.6 | 0.3 | 553.4% | |
| Inventory Days | Days | 95 | 403 | 23.5% | |
| Debtors Days | Days | 108 | 171 | 63.1% | |
| Net fixed assets | Rs m | 213,178 | 55,432 | 384.6% | |
| Share capital | Rs m | 2,399 | 268 | 895.6% | |
| "Free" reserves | Rs m | 378,606 | 13,935 | 2,716.9% | |
| Net worth | Rs m | 381,006 | 14,701 | 2,591.7% | |
| Long term debt | Rs m | 17,721 | 9,478 | 187.0% | |
| Total assets | Rs m | 643,028 | 73,988 | 869.1% | |
| Interest coverage | x | 9.6 | -0.4 | -2,692.8% | |
| Debt to equity ratio | x | 0 | 0.6 | 7.2% | |
| Sales to assets ratio | x | 0.4 | 0.1 | 424.5% | |
| Return on assets | % | 4.9 | 0.5 | 978.4% | |
| Return on equity | % | 6.9 | -27.3 | -25.4% | |
| Return on capital | % | 10.0 | -6.4 | -156.0% | |
| Exports to sales | % | 0 | 25.9 | 0.0% | |
| Imports to sales | % | 0 | 0.2 | 0.0% | |
| Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
| Imports (cif) | Rs m | NA | 12 | 0.0% | |
| Fx inflow | Rs m | 40,816 | 1,860 | 2,194.7% | |
| Fx outflow | Rs m | 30,143 | 25 | 121,106.5% | |
| Net fx | Rs m | 10,673 | 1,835 | 581.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 39,072 | 1,719 | 2,273.3% | |
| From Investments | Rs m | -33,708 | -3,148 | 1,070.7% | |
| From Financial Activity | Rs m | -15,393 | 1,426 | -1,079.4% | |
| Net Cashflow | Rs m | -7,359 | -3 | 216,444.1% | |
Share Holding
| Indian Promoters | % | 63.7 | 33.9 | 187.9% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 5.1 | 0.0 | - | |
| FIIs | % | 23.0 | 9.9 | 232.3% | |
| ADR/GDR | % | 0.0 | 16.9 | - | |
| Free float | % | 8.3 | 39.3 | 21.1% | |
| Shareholders | 133,026 | 21,482 | 619.2% | ||
| Pledged promoter(s) holding | % | 0.5 | 55.9 | 0.9% |
Compare SUN PHARMA With: ALEMBIC PHARMA FRESENIUS KABI ONCO. GLENMARK PHARMA ASTRAZENECA PHARMA DISHMAN PHARMA
Compare SUN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)
Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.
Related Views on News
SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)
Aug 16, 2018 | Updated on Aug 16, 2018For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)
May 28, 2018 | Updated on May 28, 2018For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
More Views on NewsMost Popular
Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)
Mar 8, 2019History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?
Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)
Mar 7, 2019Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...
The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)
Mar 7, 2019India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?
Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)
Mar 6, 2019Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?
The Jet Airways Crisis in 6 Charts(Sector Info)
Mar 5, 2019What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...
More|
| |
SUN PHARMA SHARE PRICE
Mar 18, 2019 (Close)
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.